| pubmed-article:3421277 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3421277 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3421277 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:3421277 | lifeskim:mentions | umls-concept:C0007004 | lld:lifeskim |
| pubmed-article:3421277 | lifeskim:mentions | umls-concept:C0040349 | lld:lifeskim |
| pubmed-article:3421277 | lifeskim:mentions | umls-concept:C0231199 | lld:lifeskim |
| pubmed-article:3421277 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3421277 | pubmed:dateCreated | 1988-10-18 | lld:pubmed |
| pubmed-article:3421277 | pubmed:abstractText | This prospective study was designed to evaluate the effects on glucose metabolism of terbutaline used as an oral tocolytic agent. Eighty-six patients were studied when admitted for preterm labor from 24 to 35 weeks' gestation. After intravenous tocolysis, these patients were maintained on 5 mg of terbutaline every 4 or 6 hours. An oral 50 gm, 1-hour glucose challenge test was done 48 hours after terbutaline dosing began. All abnormal glucose challenge test results (greater than or equal to 135 mg/dl) were followed by a standard 100 gm oral glucose tolerance test. Sixty-three percent (54 of 86) of the terbutaline group had an abnormal 1-hour screening result, which was significantly different than the 26.7% (23 of 86) observed in the control group (p less than 0.001). The mean fasting blood sugar and 1-hour postchallenge values were significantly higher in the study than in the control group (p less than 0.0001). Ten of 86 in the treated group (11.6%) and 2 of 86 in the control group (2.3%) with abnormal results met the criteria for gestational diabetes. These numbers achieve statistical significance at p less than 0.05. This study shows a significant effect of oral terbutaline therapy on glucose tolerance during pregnancy. Patients receiving oral terbutaline therapy for suppression of preterm labor should undergo screening for gestational diabetes. | lld:pubmed |
| pubmed-article:3421277 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3421277 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3421277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3421277 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3421277 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3421277 | pubmed:issn | 0002-9378 | lld:pubmed |
| pubmed-article:3421277 | pubmed:author | pubmed-author:RaffH VHV | lld:pubmed |
| pubmed-article:3421277 | pubmed:author | pubmed-author:KnuppelR ARA | lld:pubmed |
| pubmed-article:3421277 | pubmed:author | pubmed-author:AngelJ LJL | lld:pubmed |
| pubmed-article:3421277 | pubmed:author | pubmed-author:O'BrienW FWF | lld:pubmed |
| pubmed-article:3421277 | pubmed:author | pubmed-author:MoralesW JWJ | lld:pubmed |
| pubmed-article:3421277 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3421277 | pubmed:volume | 159 | lld:pubmed |
| pubmed-article:3421277 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3421277 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3421277 | pubmed:pagination | 762-6 | lld:pubmed |
| pubmed-article:3421277 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:meshHeading | pubmed-meshheading:3421277-... | lld:pubmed |
| pubmed-article:3421277 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3421277 | pubmed:articleTitle | Carbohydrate intolerance in patients receiving oral tocolytics. | lld:pubmed |
| pubmed-article:3421277 | pubmed:affiliation | Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa. | lld:pubmed |
| pubmed-article:3421277 | pubmed:publicationType | Journal Article | lld:pubmed |
